GlassScriptPhysician profile
Manish Desai
NPI 1881699080
$7,006.94
in general payments reported to CMS, 2019-2025
30 companies · $1,534 in 2025
The $1,534 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $677 · 2021: $385 · 2022: $504 · 2023: $1,011 · 2024: $1,402 · 2025: $1,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,915 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,915.02 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,916.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,087.22 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $720.68 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $584.90 | 2019-2022 | |
| Abbvie INC. | $374.82 | 2021-2024 | Qulipta, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $295.80 | 2022-2025 | Austedo Xr, Austedo, Ajovy |
| Amgen INC. | $279.14 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.73 | 2019-2024 | Jardiance |
| Pfizer INC. | $250.22 | 2019-2025 | |
| Exact Sciences Corporation | $214.37 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $190.14 | 2023-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $186.14 | 2019-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $104.49 | 2022-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $68.51 | 2020-2021 | |
| Abbott Laboratories | $66.17 | 2025 | Freestyle Libre 3, Proclaim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $60.78 | 2020 | |
| Collegium Pharmaceutical, INC. | $52.22 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.20 | 2020-2023 | Eliquis |
| Dexcom, INC. | $35.75 | 2023-2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $32.41 | 2020 | |
| Neurocrine Biosciences, INC. | $25.54 | 2025 | |
| Hikma Pharmaceuticals USA | $24.64 | 2020 | |
| Sk Life Science, INC. | $22.37 | 2025 | |
| Sanofi Pasteur INC. | $18.93 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.89 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.69 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.21 | 2024 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $13.25 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $11.14 | 2019 | |
| Circassia INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.